ArticleNature communications2015
Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria.
Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Innovative perspectives on the discovery of small molecule antibiotics.npj antimicrobials and resistance · 2025Review
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- Antimicrobial Activity of 2-(Piperazin-1-yl)naphtho[2,3-d]thiazole-4,9-dione against Staphylococcus Strains.Molecules (Basel, Switzerland) · 2024Article
- Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.npj antimicrobials and resistance · 2023Review
- Nybomycin inhibits both types ofAntimicrobial agents and chemotherapy · 2023Article
- Rationalizing the generation of broad spectrum antibiotics with the addition of a positive charge.Chemical science · 2021Article
- Synthetic Natural Product Inspired Cyclic Peptides.ACS chemical biology · 2021Article
- Facilitating Compound Entry as a Means to Discover Antibiotics for Gram-Negative Bacteria.Accounts of chemical research · 2021Review
- Towards the sustainable discovery and development of new antibiotics.Nature reviews. Chemistry · 2021Review
- Instructive Advances in Chemical Microbiology Inspired by Nature's Diverse Inventory of Molecules.ACS infectious diseases · 2020Review
- Identification and engineering of 32 membered antifungal macrolactone notonesomycins.Microbial cell factories · 2020Article
- Designing cyclic competence-stimulating peptide (CSP) analogs with pan-group quorum-sensing inhibition activity inProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-AssociatedJournal of natural products · 2019Article
- Recent Progress in Natural-Product-Inspired Programs Aimed To Address Antibiotic Resistance and Tolerance.Journal of medicinal chemistry · 2019Review
- Article
- The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics.Annals of the New York Academy of Sciences · 2019Review
- Design and virtual screening of novel fluoroquinolone analogs as effective mutant DNA GyrA inhibitors against urinary tract infection-causing fluoroquinolone resistantRSC advances · 2018Article
- Article
- Counting on natural products for drug design.Nature chemistry · 2016Review
- The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.Molecules (Basel, Switzerland) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Fluoroquinolones are one of the most commonly prescribed classes of antibiotics, but fluoroquinolone resistance (FQR) is widespread and increasing. Deoxynybomycin (DNM) is a natural-product antibiotic with an unusual mechanism of action, inhibiting the mutant DNA gyrase that confers FQR. Unfortunately, isolation of DNM is difficult and DNM is insoluble in aqueous solutions, making it a poor candidate for development. Here we describe a facile chemical route to produce DNM and its derivatives. These compounds possess excellent activity against FQR methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci clinical isolates and inhibit mutant DNA gyrase in-vitro. Bacteria that develop resistance to DNM are re-sensitized to fluoroquinolones, suggesting that resistance that emerges to DNM would be treatable. Using a DNM derivative, the first in-vivo efficacy of the nybomycin class is demonstrated in a mouse infection model. Overall, the data presented suggest the promise of DNM derivatives for the treatment of FQR infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.